Key result
In patients with dilated cardiomyopathy and severe functional mitral regurgitation, long-term mortality remains high despite optimal medical therapy, with a 5-year all-cause mortality rate of 60.0%.
Why the study?
The study was conducted to assess survival rates and clinical outcomes in patients with dilated cardiomyopathy and severe functional mitral regurgitation treated with optimal guideline-directed medical therapy.
Cohort (n=84)
No
Answers are grounded in this paper and cite their sources.
Patients with dilated cardiomyopathy and severe functional mitral regurgitation face high long-term mortality (60% over ~4 years) despite optimal medical therapy, suggesting a need for additional interventions such as mitral valve surgery.
The aim of this study was to assess survival rates and clinical outcomes in patients with dilated cardiomyopathy (DCM) and severe functional mitral regurgitation (FMR), treated with optimal guideline-directed medical therapy (GDMT).Materials and methods. After signing an informed consent, 84 patients with DCM and severe FMR were enrolled in the study. Concomitant tricuspid valve regurgitation was recorded in 82 (97.6 %) cases. The median NT-proBNP level was 2530 pg/ml (2123–3000 pg/ml).Results. Hospital mortality was 5 (6.0 %) cases. Heart transplantation was performed in 4 (5.1 %) patients; therefore long-term results were analyzed in 75 patients. During the mean follow-up period of 45.9 ± 17.6 months, the occurrence of lethal outcomes (all-cause death) was 60.0 %. The 1-, 3-, and 5-year actuarial survival rate was 84.0 %, 53.3 % and 40.0 %, respectively. Left ventricular ejection fraction and systolic pressure in the pulmonary artery were independently associated with long-term all-cause mortality.Conclusions. The study results demonstrate that the short-term and long-term mortality rates in patients with dilated cardiomyopathy and severe functional mitral regurgitation remain high despite the treatment with currently accepted pharmacological therapy. One possible method which would improve the treatment results is mitral valve surgery.
No takes yet. Share an insight, caveat, or question.
Buriak et al. (2020) conducted a cohort in Dilated cardiomyopathy with severe functional mitral regurgitation (n=84). Optimal guideline-directed medical therapy was evaluated on All-cause mortality at 5 years. In patients with dilated cardiomyopathy and severe functional mitral regurgitation, long-term mortality remains high despite optimal medical therapy, with a 5-year all-cause mortality rate of 60.0%.
Synapse has enriched 10 related papers. Consider them for comparative context: